• Corporate Event: OSI Pharmaceuticals, Inc. (OSIP) - Effective Thursday, June 10, 2010

      • To
      • Clearing Member Firms
      • From
      • CME Clearing
      • #
      • 10-245
      • Notice Date
      • 09 June 2010
      • Effective Date
      • 10 June 2010

    • On June 7, 2010, Ruby Acquisition, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc.,

      a wholly-owned subsidiary of Astellas Pharma Inc., completed its Subsequent Tender Offer for

      OSI Pharmaceuticals, Inc. (OSIP) Common Shares. The merger was subsequently consummated

      on June 8, 2010. As a result, each existing OSIP Common Share will be converted into the right to receive $57.50 net cash per share.

       

      This action will be coordinated with the Options Clearing Corporation.

      For the full text of this advisory, please click here.

       

CME Group is the world’s leading derivatives marketplace. The company is comprised of four Designated Contract Markets (DCMs). 
Further information on each exchange's rules and product listings can be found by clicking on the links to CME, CBOT, NYMEX and COMEX.

© 2025 CME Group Inc. All rights reserved.